---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-265858"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-06-10T20:15:18+00:00"
generated_at: "2026-06-10T20:22:59.420873+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics shareholders re-elect two directors, ratify auditor at 2026 annual meeting

## Summary
- Quorum of 44,660,029 shares (89.75% of outstanding) present at June 8 meeting.
- Jason Coloma re-elected with 35,792,536 votes for, 5,926,467 withheld.
- Neil Kumar re-elected with 34,056,425 votes for, 7,662,578 withheld.
- Ratification of Ernst & Young as auditor passed: 44,557,778 for, 728 against.
- No broker non-votes on auditor ratification; 2,941,026 broker non-votes on director election.

## SEC filing metadata
- accession: 0001193125-26-265858
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-06-10T20:15:18+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/d110541d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-265858
- JSON: https://secwatch.observer/filing/0001193125-26-265858.json
- Plain text: https://secwatch.observer/filing/0001193125-26-265858.txt

## Key facts
- Shareholder Votes
  Maze Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-08
  source text: Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 44,557,778 728 101,523 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm
- Shareholder Votes
  Maze Therapeutics, Inc. shareholders approved To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders at the 2026-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-08
  source text: Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Jason Coloma, Ph.D. 35,792,536 5,926,467 2,941,026 Neil Kumar, Ph.D. 34,056,425 7,662,578 2,941,026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/0001193125-26-265858-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.